Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/29/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. GAP
8. DG
9. ULTA
10. NVDA

Go back to Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess
(NASDAQ: HUMA) Delayed: 0.65 -0.04 (5.8%)
Previous Close $0.69    52 Week High $ 
Open $0.69    52 Week Low $ 
Day High $0.70    P/E N/A 
Day Low $0.64    EPS $ 
Volume 4,921,513